Syros Pharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 19:2519:25, 20 August 2022 95.149.241.133 talk 1,226 bytes +11 No edit summary undo

14 August 2022

• curprev 05:5005:50, 14 August 2022 109.180.50.163 talk 1,215 bytes +15 No edit summary undo

31 July 2022

• curprev 09:0309:03, 31 July 2022 >Chris 1,200 bytes +1,200 Created page with "Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2..."